Trial · NCT06362707
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
NCT06362707, Phase 2, Recruiting, Helse Stavanger HF
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD). Trials, record NCT06362707. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06362707
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
- NCT number
- NCT06362707
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Helse Stavanger HF
- Conditions
- Cognitive Decline, Mild, Alzheimer Disease
- Interventions
- Fasudil, Placebo
- First posted
- 2024-04-12
- Last updated
- 2026-05-04
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cognition | The cognitive battery will be performed at baseline and every three months until last visit, supported by trial staff (up to 1 year). | The primary outcome will be the FLAME computer-based working memory composite comprised of tests of working memory and episodic memory |
| Primary | Brain metabolism | The outcome will be change in FDG-PET between baseline and at 12 months. | FDG-PET is a highly sensitive means of determining brain metabolism and has been accepted as a good proxy measure of synaptic function. Importantly, FDG-PET based measures of brain metabolism correlate well with cognitive decline in AD, better than amyloid plaques. Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study suggest that FDG PET has good power to detect a 25% treatment effect over 12 months |
| Secondary | Plasma levels of ptau217 | Collection of blood samples will occur at baseline and the 12-month visit. | This study involves the collection of blood samples, following standardized procedures. Blood markers associated with Alzheimer's disease (AD) will be analyzed for typical AD features to fulfill inclusion criteria. The primary focus will be on examining changes in levels of plasma ptau217 and nfl, measured in pg/mL. |
| Secondary | Plasma levels of nfl | Collection of blood samples will occur at baseline and the 12-month visit. | This study involves the collection of blood samples, following standardized procedures. Blood markers associated with Alzheimer's disease (AD) will be analyzed for typical AD features to fulfill inclusion criteria. The primary focus will be on examining changes in levels of plasma ptau217 and nfl, measured in pg/mL. |
| Secondary | Levels of cerebrospinal Aβ1-40 and Aβ1-42 | Collection of CSF samples will occur at baseline and the 12-month visit. | This study involves the collection of cerebrospinal fluid (CSF) samples, following standardized procedures. CSF markers associated with Alzheimer's disease (AD) will be analyzed for typical AD features, measured in pg/mL. |
| Secondary | Levels of cerebrospinal tau and p-tau | Collection of CSF samples will occur at baseline and the 12-month visit. | This study involves the collection of cerebrospinal fluid (CSF) samples, following standardized procedures. CSF markers associated with Alzheimer's disease (AD) will be analyzed for typical AD features, measured in pg/mL. |
| Secondary | Blood pressure (Safety assessments) | Conducted at all visits throughout the 12-month duration of the study. Additionally, the Columbia Suicide Severity Rating Scale (C-SSRS) will be administered at screening, month 6, and month 12 | Safety measurements, blood pressure measured in millimetres of mercury (mmHg). |
| Secondary | Pulse (Safety assessments) | Conducted at all visits throughout the 12-month duration of the study. | Safety measurements, including pulse frequency in beats per minute (bpm). |
| Secondary | Urine testing (Safety assessments) | Conducted at baseline and all visits throughout the 12-month duration of the study. | Urine will be tested with a dipstick test to explore proteinuria or hematuria. |
| Secondary | Blood urea nitrogen (BUN) (Safety assessments) | Conducted at baseline and all monthly visits throughout the 12-month duration of the study. | Measured in blood in mmol/L |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers40
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06362707
GET https://conductscience.org/api/trials/v1/NCT06362707/registered?page=2